Druggability & Clinical Context
Druggability
Undruggable
Score: 0.23
Target Class
Structural Protein
Druggability Analysis
Structural Tractability0.30
Key Metrics
PDB Structures:
0
Known Drugs:
4
Approved:
1
In Clinical Trials:
1
Drug Pipeline (4 compounds)
1 Approved · 2 Preclinical
Therapeutic Areas:Non-alcoholic fatty liver disease (NAFLD) Neuroinflammation associated with lipid accumulation Alzheimer's disease and amyloid-related pathology Parkinson's disease with metabolic dysfunction Lysosomal storage disorders with lipid component Obesity and metabolic syndrome with neurological manifestation Neuronal lipotoxicity and cellular stress
Druggability Rationale: PLIN2 presents low druggability due to its structural protein classification lacking typical deep binding pockets required for small-molecule inhibitors, compounded by the absence of crystal structures (PDB unavailable, 0 structures) that would facilitate rational drug design. However, precedent exists through indirect modulators (thiazolidinediones) and lipase inhibitors (GSK2163511, atglistatin) that alter PLIN2 function via upstream pathway modulation rather than direct binding, suggesting alternative drugging strategies beyond orthosteric inhibition.
Mechanism: Direct PLIN2 inhibitors would reduce lipid droplet formation and stability, promoting lipid mobilization and reducing pathological lipid accumulation. Indirect approaches target upstream regulators of PLIN2 expression or modulate associated lipases to alter lipid storage dynamics in metabolic and neurodegenerative disease states.
Drug Pipeline (4 compounds)
1 Approved · 2 Preclinical
Known Drugs:Atglistatin (preclinical) — Lipid metabolism disorder; research tool for adipose triglyceride lipase inhibition
A-922500 (preclinical) — Obesity and metabolic dysfunction; adipose triglyceride lipase inhibitor
GSK2163511 (phase1) — Non-alcoholic fatty liver disease (NAFLD); adipose triglyceride lipase inhibitor affecting lipid droplet dynamics
Thiazolidinediones (pioglitazone, rosiglitazone) (approved) — Type 2 diabetes; indirect modulation of lipid droplet proteins and lipid metabolism pathways
Structural Data:PDB —AlphaFold ✓Cryo-EM —
Binding Pocket Analysis:No characterized binding pockets are defined due to lack of structural data; AlphaFold predictions are available but unvalidated experimentally. PLIN2 likely functions through protein-protein interactions with lipid droplet surface components and lipases rather than harboring conventional small-molecule binding sites, suggesting that successful inhibition may require peptide antagonists, monoclonal antibodies, or indirect pathway modulation rather than small-molecule drugs.
Selectivity & Safety Considerations
PLIN2 is one of five perilipin family members (PLIN1-5) with overlapping lipid droplet localization and function, creating significant selectivity challenges for direct inhibitors. Off-target engagement with PLIN1, PLIN3, or associated lipases (ATGL, HSL) could confound therapeutic efficacy and safety, necessitating structure-guided approaches or isoform-selective allosteric modulators.
Clinical Trials (5)
Relevant trials from ClinicalTrials.gov
By Phase
NA: 3 · Unknown: 2
NA
NCT05012514
n=10
Photobiomodulation
Interventions: LLLT RED
Sponsor: Indústria Brasileira Equipamentos Médicos - IBRAMED | Started: 2020-08-08
Unknown
NCT02923284
n=407
Renal Cell Carcinoma, Renal Cell Cancer
Sponsor: Washington University School of Medicine | Started: 2016-08
NA
NCT01997060
n=80
Obesity, Overweight
Interventions: Intensive Lifestyle Intervention
Sponsor: University of Copenhagen | Started: 2014-01
NA
NCT04247464
n=11
Fasting
Interventions: Fasting
Sponsor: IMDEA Food | Started: 2020-09-23
Unknown
NCT01997034
n=80
Obesity, Overweight
Interventions: Intensive Lifestyle Intervention
Sponsor: University of Copenhagen | Started: 2013-11